Amylin’s SymlinPen To Launch In December
Firm gets mixed blessing from FDA as agency says combination of pramlintide and basal insulin is "not approvable."
Firm gets mixed blessing from FDA as agency says combination of pramlintide and basal insulin is "not approvable."